You are here: Industry Insights > Market News > Zydus Cadila receives tentative approval from US FDA for Cariprazine Capsule

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Zydus Cadila receives tentative approval from US FDA for Cariprazine Capsule

expresspharmaDecember 13, 2021

Tag: Cariprazine , Zydus , Capsule

Favorites

Zydus Pharmaceuticals Inc has received tentative approval from the United States Food and Drug Administration (FDA) to market Cariprazine Capsules in the strengths of 1.5 mg, 3 mg, 4.5 mg and 6 mg, the company notified via a statement.

It also said that Cariprazine is an atypical antipsychotic. Zydus’ Cariprazine Capsules are indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar disorder. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

Previous:Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021

Next:Proximie Partners with Jhpiego in New Initiative to Improve Obstetric Surgical Care

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

Nucleic Acid Medicines Manufacture, Round 2 call.

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Biotech NewswireMay 09, 2024

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

Biotech NewswireMay 09, 2024

Zydus Cadila receives tentative approval from US FDA for Cariprazine Capsule | Pharmasources.com

On the Path to Net Zero: Vetter Achieves New Sustainability Goals in 2023

Biotech NewswireMay 09, 2024

Alongside its dynamic growth, Vetter announced that it achieved its sustainability goals for 2023.

Zydus Cadila receives tentative approval from US FDA for Cariprazine Capsule

Related News

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

On the Path to Net Zero: Vetter Achieves New Sustainability Goals in 2023

You may like